sch-900353
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01358331)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- MAP kinase ERK2INHIBITOR
MAPK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1- Mol. weight
- 691.86 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4213970 ↗
- ChEMBLCHEMBL3545001 ↗
Also known as
- mk-8353
- mk-8353
- sch-900353
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03745989 | Phase 1 | Feb 22, 2019 | Merck |
| NCT02972034 | Phase 1 | Jan 13, 2017 | Merck |
| NCT01358331 | Phase 1 | Nov 1, 2011 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 1 | 2011 |
1 organizations
Page 1 / 1